However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
Grandi V, Milanesi N, Sessa M, Gola M, Cappugi P, Pimpinelli N.G Ital Dermatol Venereol
Values between 5.7% and 6.4% indicate prediabetes, a condition affecting millions of Canadians who often remain unaware of their elevated risk
extraction blanks) were applied to exclude/define potential contaminating microbial DNA originating from the extraction kit and other reagents used for sample DNA processing
Similarly, individuals with metabolic disorders or impaired pancreatic function may experience altered responses to semaglutide